Caption Management’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$20.7M Buy
355,700
+65,700
+23% +$3.03M 0.12% 178
2025
Q4
$13M Buy
290,000
+230,000
+383% +$9.66M 0.09% 265
2025
Q3
$2.41M Sell
60,000
-106,200
-64% -$3.74M 0.02% 771
2025
Q2
$5.2M Buy
+166,200
New +$5.42M 0.06% 396
2024
Q1
Sell
-190,700
Closed -$8.78M 1717
2023
Q4
$8.78M Buy
190,700
+3,700
+2% +$131K 0.12% 200
2023
Q3
$6.39M Buy
+187,000
New +$6.99M 0.1% 257
2021
Q4
Sell
-422,200
Closed -$6.45M 1987
2021
Q3
$6.45M Buy
+422,200
New +$7.34M 0.07% 358

Other funds holding XENE

Caption Management's XENE Position: Q3 2025 in Review

Caption Management sold out of Xenon Pharmaceuticals (XENE) in Q3 2025, closing a stake of 100,940 shares — an estimated $3.56M sold.

Caption Management first reported a position in XENE in Q3 2023 and held it in 2 quarters. The position peaked at $3.16M in Q2 2025. 219 funds tracked by Wall St. Rank hold XENE as of Q3 2025.

  • Caption Management reported no remaining Xenon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Caption Management sold 100,940 Xenon Pharmaceuticals shares in Q3 2025, an estimated $3.56M.
  • Caption Management first reported a position in Xenon Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Caption Management's Xenon Pharmaceuticals position peaked at $3.16M in Q2 2025.
  • 219 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2025.

Based on Caption Management's 13F filing for Q3 2025, filed 14 Nov 2025.